Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacyResearch in context
Background: Bringing antibodies from pre-clinical studies to human trials requires humanization, but this process may alter properties that are crucial for efficacy. Since pathological tau protein is primarily intraneuronal in Alzheimer's disease, the most efficacious antibodies should work both int...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2019-04-01
|
| Ráidu: | EBioMedicine |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2352396419301732 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|